

CURRICULUM VITAE

INVESTIGATOR NAME: Andrés Francisco Alvarisqueta
INVESTIGATOR NATIONALITY: Argentine
LICENSE NUMBER: 92008
STUDY LOCATION ADDRESS: Centro de Investigaciones Médicas Mar del Plata
Mail: andres.alvarisqueta@cimmdp.com
Av. Colón 3083, 1º, 4º, 5º and 7º floor, B7600FYK Mar del Plata. Bs.
As. Argentina Tel:+ 54 223 491-7628 / 495-6654

EDUCATION: List Colleges/ Universities attended with dates and degrees obtained
1975-1980 Universidad Nacional de Buenos Aires. Facultad de Medicina
Degree: Physician

POSTGRADUATE: Specialty, dates, institution's name

1982-1985: Residency Chief of Internal Medicine. Hospital Privado de Comunidad. Mar del Plata
1999: Densitometrist. International Society for Clinical Densitometry.
2003-2005: Master in Clinical Pharmacology Universidad Abierta Interamericana.
JUN 2006 Journals of GCP Scientific Methods and GCP. Dictated by Dr Ruben Iannantuono. Mar del Plata
-Training Certificated Of Good Clinical Practice (GCP). Ministerio de Salud 18 September 2018.
-Training in Ethics of the research. Conducted by Dr. Ignacio Maglio. Aug 2017
-Sep 2018- Course of Ethics and Good Clinical Research Practices. Ministerio de Salud de la Nación, duration 80 hs
-July 2019- Good Clinical Research Practices. Brookwood
-July 2022- Good Clinical Research Practices NIDA Clinical Trials Network

PROFESSIONAL EXPERIENCE:

· Board certification/ Name of board:
Specialist in Internal Medicine. Colegio de Médicos de la Pcia. De Buenos Aires IX Distrito 1986
· Previous appointments (List positions held, gives dats and institutions):
1982-1985: Residency Chief of Internal Medicine. Hospital Privado de Comunidad. Mar del Plata
1983: Residency Chief (4 months)
1984: External physician's Office of internal medicine. Hospital Privado de Comunidad. Mar del Plata
1985: Residency chief of Internal Medicine. Hospital Privado de Comunidad. Mar del Plata
1986: Residency Instructor of Internal Medicine. Hospital Privado de Comunidad. Mar del Plata
1987-1989: Emergency room physician. Hospital Privado de Comunidad. Mar del Plata
1990-2003: Clinical Medicine service coordinator. Clínica de Fracturas y Ortopedia. Mar del Plata
2003-2007: Member of Clinical Trials Unit. Clínica Colón. Mar del Plata
1992-2006: Medical Director, Centro de Osteopatías Metabólicas Clínica de Fracturas y Ortopedia Mar del Plata.
2006 - 2014: Medical Director, Centro de Investigaciones Médicas Clínica de Fracturas Y Ortopedia. Mar del Plata
· Present appointment:
Since 1992 to present date Coordinator of DxAs service. Centro de Osteopatías Metabólicas
Since 1992 to present, Medical Director. Centro de Osteopatías Metabólicas
Since 2006-2014, Medical Director Centro de Investigaciones Médicas. Clínica de Fracturas y Ortopedia Mar del Plata.
Since 2014 to present date, Institutional Director of "Centro de Investigaciones Médicas Mar del Plata."

PROFESSIONAL EXPERIENCE IN CLINICAL INVESTIGATION:

CHARISMA Phase III Cardiovascular Prevention. Antiplatelets. 2002-2005. Principal Investigator.
CVT1 Phase III Cardiovascular Diagnostic, Ischemia marker Quality Assurance. 2004. Sub Investigator.
CVT2 Phase III Ischemia marker Quality Assurance. 2005. Sub Investigator.
OASIS 6 Phase III Acute ischemic, ischemic marker. 2005-2006. Co investigator.
ORIGIN Phase III Diabetes. Cardiovascular prevention. 2005-2006. Co investigator.

CLAF 2308 Phase III Diabetes. 2005-2007. Principal Investigator.
CLAF 2310 Phase III Diabetes. 2005-2007. Principal Investigator.
SERENADE Phase III Diabetes. 2005-2006. Principal Investigator.
SIADH Phase III Dilutional Hyponatremia Acuaretic. 2005-2006. Principal Investigator.
DILIPO Phase III Dilutional Hyponatremia Acuaretic. 2005-2006. Principal Investigator.
ATHENA Phase III Atrial fibrillation. 2005. Principal Investigator.
SYR472-007 Phase II Diabetes. 2007. Principal Investigator (*selected center, not initiated study*)
OPI-001 Phase III Diabetes. 2007. Principal Investigator (*selected center, not initiated study*)
OPI-002 Phase III Diabetes. 2007. Principal Investigator (*selected center, not initiated study*)
OLE Phase III y IIIb Diabetes. 2007. Principal Investigator (*selected center, not initiated study*)
DRIVE Phase II TVP Profilaxis enti II anti X. 2006-2007. Principal Investigator.
CLAF2338 Phase III Diabetes. 2007-2008. Principal Investigator.
CZOL446M2309 Phase III Osteoporosis. Since 2007. Principal Investigator.
ROCKET Phase III. Atrial fibrillation. 2007-2010. Principal Investigator.
EFC10342 HIP 1 Hip replacement. 2008-2009. Principal Investigator.
EFC10343 HIP 2 Hip fracture. 2008-2009. Principal Investigator.
EFC10571 Knee replacement. 2008-2009. Principal Investigator.
RADIUS Phase II Osteoporosis in woman. 2007-2009. Principal Investigator.
CRESCENDO Phase III Cardiovascular risk. 2007-2008. Principal Investigator.
D1680C0002 Phase IIIb. 2008-2009. Principal Investigator.
BI 1218.18 Phase III. 2008-2009. Principal Investigator.
GETGOAL X Diabetes. 2008-2011. Principal Investigator.
CLAF 23137 Bad controlled diabetes with renal failure. Since 2008. Principal Investigator.
BC21713 Diabetes. Since 2009. Principal Investigator.
RAD 00-001 Observational study. Hot flashes. 2008-2009. Principal Investigator.
RAD1901002 Hot flashes. 2008-2009. Principal Investigator.
BII245.9 Phase II Diabetes. Since 2009. Principal Investigator.
BII245.10 Phase II Diabetes. Since 2009. Principal Investigator.
BOREALIS Phase III Atrial fibrillation. 2008-2010. Principal Investigator.
ATLAS II Phase II Acute coronary syndrome. Since 2009. Principal Investigator.
DAPA 10 Phase IIIb Diabetes. Since 2010-2012. Principal Investigator.
CACZ Phase IIb y III Diabetes. Since 2010-2011. Principal Investigator.
DIA3008 Phase III Diabetes. Since 2010-2017. Principal Investigator.
AFICIONADO Phase IV. Diabetes. Since 2010-2014. Principal Investigator.
TECOS Phase III. Diabetes. Since 2010-2014. Principal Investigator.
FOREST Phase III. Diabetes. Since 2010-2012. Principal Investigator.
HOKUSAI Phase III. TVP/EP. 2010-2012. Principal Investigator.
D1680C0003 Phase IV. Since 2010-2011. Principal Investigator.
CHIESI Phase III COPD. Since 2010-2012. Co investigator.
ADC113874 Phase III. COPD. Since 2011-2013. Co investigator.
PEGASUS Phase III. Since 2010-2014 Principal Investigator.
CLCZ696B2314 Phase III. Since 2011.-2014 Principal Investigator.
EFC11319 Phase III. Since 2011-2013. Principal Investigator.
IMAGINE 2 Phase III. Diabetes. Principal Investigator.
D5896C00027 Phase IV Asthma. Since 2012. Sub Investigator.
HZC113782 Phase III COPD. Since 2012. Sub Investigator.
HZA106853 Phase III COPD. Since 2012. Sub Investigator.
SAS115358 Fase IIIb. Asthma in Children. Since 2013-2016. Sub Investigator.
CQAB149B2401 Phase III COPD. Since 2012-2014. Sub Investigator.
B3D-EW-GHDW Phase IV Osteoporosis. Since 2012-2017. Principal Investigator.
EUCLID Phase IIIb Peripheral vascular disease. Since 2013-2016 Principal Investigator.
ODYSSEY Phase IIIb. Acute coronary syndrome. Since 2013. Principal Investigator.
JADZ Phase III Rheumatoid Arthritis. Since 2013-2015. Sub Investigator
JADV Phase III Rheumatoid Arthritis. Since 2013-2015. Sub Investigator
DIA3011 Phase III. Diabetes type II. Since 2013-2015. Principal Investigator.
CALIMA-D3250C00018. Phase III. Uncontrolled asthma. Since 2014-2016. Sub Investigator
MEDIVECTOR Phase III. Not complicated influenza. Since 2014-2015. Sub Investigator
AMGEN20110142. Phase III. Osteoporosis. Since 2014-2017. Principal Investigator
B12610007 Phase III. Diabetic nephropathy. Since 2014-2015. Principal Investigator
DECLARE Phase IIIb. Diabetes type II and cardiovascular risk. Since 2014. Principal Investigator

CQVA Phase III. COPD. Since 2014-2016 Sub Investigator
3251C00021 BORA Phase III COPD 2015-2016 Sub investigator
MK-018. Phase III. Diabetes type II and cardiovascular risk. Since 2014-2016. Principal Investigator.
NN-95353626. Phase IIIa. Diabetes type II and Metformina failure. Since 2014-2016. Sub Investigator
DIA4003. Phase III. Diabetes II and cardiovascular risk. Since 2014-2017. Principal Investigator.
JADY. Phase III. Rheumatoid arthritis. Since 2015. Sub Investigator
BCB109 Phase III Diabetes II. Since 2014-2017 Principal Investigator
MK 8835-001. Phase III .Diabetes Since 2015 to 2016. Principal Investigator
MK 8835-005. Phase III. Diabetes. Since 2015 to 2016. Principal Investigator
HARMONY. Phase III/IV. Diabetes with cardiovascular events. Since 2015-2019. Principal Investigator
CTT116855 fase III,COPD 2015-2017 Sub Investigador
ABBVIE M11-352. Phase III Kidney failure and diabetes. Since 2015-2018 Principal Investigator
D513BC00001THEMIS. Phase III.Diabetes with cardiovascular risk. Since 2015-2019. Principal Investigator
GEMINI. Phase III. Cardiovascular event 2016-2017. Principal Investigator
TERRANOVA. Phase III. COPD. Since 2015-2018 Sub Investigator.
MARINER Phase III. Risk of venous thromboembolism at discharge. Since 2015-2017. Principal Investigator
CV185316 AUGUSTUS. Phase IV. Atrial fibrillation and acute coronary syndrome. Since 2016-2019. Principal Investigator
AP611074 CT4. Phase II. Condyloma. Since 2016-2018. Principal Investigator
OLYMPUS. Phase III. Chronic Renal Failure with Anemia. Since 2016-2019 Principal Investigator
CREDENCE. Phase III. Chronic Renal Failure with diabetes Since 2016-2018 Principal Investigator
VOYAGER. Phase III. Risk of thrombotic vascular events.Since 2016 Principal Investigator
GA 28949. Phase III.. Moderate to severe ulcerative colitis Since 2017. Principal Investigator
GA 28951. Phase II/III Extensión. Moderate to severe ulcerative colitis. Since 2017 Principal Investigator
PT010005 Phase III COPD. Since 2017. Sub Investigator.
PT009003 SOPHOS.Phase III COPD. Since 2017-2018 Sub investigator
MK0431-848. Phase III DBT 2. Since 2017-2018. Principal Investigator
MK0431/845 Phase III. DBT 2. Since 2017-2018. Principal Investigator
MK8835-004-01/B1521021. Phase III Diabetes 2 with established vascular disease Since 2017. Sub Investigator.
ASCEND-200808 Phase III. Anemia associated with chronic kidney disease. Since 2017. Principal Investigator .
AKB-6548-CI-0015. Phase III. Anemia associated with chronic kidney disease. Since 2017. Principal Investigator
AKB-6548-CI-0014. Phase III. Anemia associated with chronic kidney disease. Since 2017. Principal Investigator
DAPA CKD- D169AC00001. Phase III. Chronic renal disease. Since 2017 . Principal Investigator
DAPA HF D1699C00001. Phase III. Chronic heart failure with reduced ejection fraction. 2017-2019 Sub Investigator
MNK4049. Phase III. Focal and segmental sclerosis. Since 2017-2019 Principal Investigator
MLN0002SC-3030 Phase IIIb ulcerative colitis Since 2017-2018Principal Investigator
MLN0002SC-3031 Phase III. ulcerative colitis Since 2017-2018 Principal Investigator
PROMINENT. Phase III. Cardiovascular disease, triglyceride reduction in diabetic patients. Since 2017. Principal Investigator
ETC1002-043CLEAR OUTCOMES. Phase III. Intolerance to statins with cardiovascular risk. Since 2017. Principal Investigator
GA29350 Phase II Rheumatoid arthritis.. Since 2017. Sub Investigator
GA30067 extention Phase II Rheumatoid arthritis.. Since2018 Sub Investigator.
BII245.110. Phase III.. Chronic heart failure with preserved ejection fraction . Since 2018. Principal Investigator
BI 1245.121. Phase III Chronic heart failure with reduced ejection fraction. Since 2018. Principal Investigator
EFC14875. SCORED Phase III Cardiovascular and renal events in patients with DBT II, cardiovascular risk factors and moderate failure. Since 2018. Sub Investigator
EFC14837 Phase III Diabetes with moderate renal disease. Since 2018 Sub Investigator
EFC15116 Phase III Diabetes with severe kidney disease. Since 2018 Sub Investigator
CREDO 2 / CLO4041023. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator
CREDO 3 / CLO4041025. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator

205270 Phase III Anemia associated with chronic kidney disease. Since 2018. Principal Investigator
 HZA107116. Phase III Asthma in children 5 to 17 years old. Since 2018 Sub investigator
 204837 Phase III. Dialysis patients with anemia related to chronic kidney disease. Since 2018. Principal Investigator
 CREDO 4/CLO041024. Phase III Rheumatoid arthritis Since 2019 Sub investigator
 OBS15459 Phase IV Diabetes, Observational Study Since 2019. Principal Investigator
 RLM-MD-02 Phase III diabetic gastroparesis. Since 2009 Sub investigator
 RLM-MD-03 Extension Phase III diabetic gastroparesis. Since 2009 Sub investigator
 RLM-MD-04 Phase III diabetic gastroparesis. Since 2009 Sub investigator
 DELIVER Phase III Chronic heart failure with preserved ejection fraction . Since 2019 Principal Investigator
 BOREAS Fase III. EPOC. Desde 2020. Sub Investigador
 CONTRAST 1 201790- Phase III Artritis reumatoidea. Desde 2020 Sub Investigador
 CONTRAST 2 202018- Phase III Artritis reumatoidea. Desde 2020 Sub Investigador
 TRICIDA, Fase IIIB Acidosis Metabólica. Desde 2019 Investigador Principal
 PLATFORM PACRD2001- Phase II Crohn´s Disease Sub Investigator Since 2020
 QUASAR CNTO1959UCO3001 Phase IIb/III Ulcerative colitis. Sub Investigator Since 2020
 NODE 303. Phase III. Paroxysmal Supraventricular tachycardia. Principal Investigator. Since 2020
 MIT-Do001-C301(Estetra) Phase III. Post menopausal woman with vasomotor symptoms. Principal Investigator. Since 2020
 MATINEE Phase IIIA. Epoc with eosinophilic levels. Since 2021. Sub Investigator
 AMETHYST Phase II. Heart failure with preserved FE. Since 2021. Principal Investigator
 AMEERA-5 Phase III. Breast cancer Since 2021. Sub Investigator
 213400 Phase III Non-small cell lung cancer. Since 2021 Sub Investigator
 ARENA APD334-202 Phase III. Crohn's disease. Since 2021 Sub Investigator
 MEDI3506 Phase IIb. Diabetic nephropathy. Since 2021 Sub Investigator
 1366,0022 Phase III Non-diabetic kidney disease. Since 2021 Principal Investigator
 1366,0005 Phase III Diabetic chronic kidney disease. Since 2021 Principal Investigator
 CC-93538-EE-01 Phase III Eosinophilic esophagitis. Since 2021 Principal Investigator
 ANJ900D3501 Phase III Diabetes with variable renal function. Since 2021. Principal Investigator
 D7551C00001 Phase IIb. Chronic proteinuric kidney disease. Since 2021 Principal Investigator
 DIALIZE Phase III Arrhythmia in patients on chronic hemodialysis due to recurrent hyperkalemia. Since 2021 Principal Investigator
 GKPTN Platform Study. Since 2021 Principal Investigator
 INS1007-301 ASPEN Phase III Bronchiectasis. Since 2021 Sub Investigator
 TACKLE Phase III Treatment of Covid in non-hospitalized adult patients. Since 2021 Sub Investigator
 KANGTAI Phase III Covid-19 Vaccine Since 2021 Principal Investigator
 BANNER Phase IIIA HIV Since 2021 Sub Investigator
 RPC01-3201 Moderate to severe Crohn's disease From 2022 Principal Investigator
 ZEUS Phase III Cardiovascular disease, chronic renal failure. Since 2022 Principal Investigator
 ALIGN Phase III IgA nephropathy and progressive loss of renal function. Principal Investigator
 STABILIZE Phase III Chronic kidney disease and hyperkalaemia From 2022. Sub-Investigator
 D4325C00001 ZENIT Phase IIB CKD with glomerular filtration rate between 20 and 60 ml/min/1.73 m2 Principal Investigator
 GB4311 Phase IIb COPD. Since 2022 Sub-Investigator.
 GO42784 Lidera Phase III Breast cancer. Since 2022 Sub-Investigator
 23OLE304 TOPAZ Phase III Lupus. Since 2022 Sub-Investigator
 WILLOW Phase II Lupus erythematosus. Since 2022. Sub-Investigator
 K-001-201 Phase II NASH with liver fibrosis Since 2022 Sub Investigator
 SURMOUNT I8F-MC-GPIJ Phase III Obesity. Since 2023. Principal Investigator
 RPC01-3204 Moderate to severe Crohn's disease. Since 2022 Principal Investigator
 RPC01-3203 Moderate to severe Crohn's disease. Since 2022 Principal Investigator
 CC-93538-EE-02 (Extension) Phase III Eosinophilic esophagitis. Since 2022 Principal Investigator
 BI 1378-0005 Chronic kidney disease. Since 2022. Principal Investigator
 JASMINE 80202135SLE2001 Systemic Lupus Erythematosus (SLE) Since 2023. Sub Investigator
 MS200569_0048 WILLOW LTE Phase II Lupus erythematosus Since 2023. Sub-investigator
 J2A-MC-GZGU Phase III Adults with type 2 diabetes and inadequate glycemic control with Metformin. Since 2023 Sub Investigator
 23OLE301 (AMETHYST) Phase II Cutaneous lupus erythematosus. Since 2023 Sub Investigator

EX6018-4915 HERMES Phase III Patients with heart failure and inflammation. Since 2023 Principal Investigator
70033093AFL3002 LIBREXIA AFL Phase III Patients with Atrial Fibrillation Dede 2023 Principal Investigator
70033093ACS3003 LIBREXIA ACS Phase III Acute coronary syndrome. Since 2023 Subinvestigator
CR845-310302 KICK 2 Phase III ITCH OF MODERATE INTENSITY A SEVERE IN SUBJECTS WITH CHRONIC KIDNEY DISEASE. Since 2023 Principal Investigator
ADVANCED
ACTIV-2b SCORPIO-HR Phase III Non-hospitalized patients with COVID-19 Since 2023 Sub-investigator
AT-03A-017 Phase III High-risk outpatients with COVID-19. Since 2023 Subinvestigator
209978 MARS-17 Phase II Osteoarthritis of the knee. Since 2023 Subinvestigator
AMG592 20170104 Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
AMG592 20210210 EXT Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
CNT01959UCA3004 ASTRO Phase III Moderately to severely active ulcerative colitis. Since 2023 Subinvestigator
K-001-201 Phase II NASH. Since 2023 Subinvestigator
BUS-P3-01 CALM Bellus Phase III Refractory chronic cough. Since 2023 Sub Investigator
EDP 938-104 ENANTA Phase IIb Acute syncytial respiratory virus. Since 2023 Subinvestigator
GB43374 OLE COPD Since 2023 Sub-researcher
CLI-06001AA1-04 PILASTER Phase III COPD Since 2023 Sub Investigator
CLI-06001AA1-05 PILAR Phase III COPD Since 2023 Sub Investigator
CLI-05993AA-06 TRITON Phase III COPD Since 2023 Sub Investigator
1368-0098 Phase IIb/III. Hidradenitis suppurativa. Since 2023 Sub Investigator
INCB 18424-319 Phase III Prurigo nodularis. Since 2023 Sub Investigator
77242113PSO3001 Phase III Moderate to severe plaque psoriasis. Since 2023 Sub Investigator
1366-0031 Phase II Cutaneous sclerosis. Since 2023 Sub Investigator
D6970C00002 BaxHTN Phase III Participants with Hypertension Uncontrolled on Two or More Medications including Participants with Resistant Hypertension Since 2024 Principal Investigator
MK 7240-001 CU Phase III participants with moderately to severely active ulcerative colitis Since 2024 Principal Investigator
219700 VOLITION Phase IIIb HIV-1 in antiretroviral therapy-naïve adults Sub Investigator Since 2024
23OLE306 (EMERALD) Phase III Systemic lupus erythematosus. Since 2024 Sub Investigator
D4325C00007 Chronic kidney disease and proteinuria. Since 2024 Sub Investigator
D7830C00004 FORTUNA Phase IIb. Non-alcoholic non-cirrhotic steatohepatitis with fibrosis (NASH) Since 2024 Sub Investigator
D4325C00010 ZENITH Phase III Chronic kidney disease and high proteinuria. Since 2024 Sub Investigator
MRXC-302 Phase III Moderate disease or severe diabetic foot infections. Since 2024 Sub Investigator
ACT17746 LIBERTY Phase II Ulcerative colitis with eosinophilic profile. Since 2024 Sub Investigator
78934804UCO2001 (DUET-UC) Phase IIb Moderately to severely active ulcerative colitis. Since 2024 Sub Investigator

DATE: 15 Jan 2024

SIGNATURE:


Dr. Andres Alvarisqueta
CLÍNICA MÉDICA
M.P. 92008